Klcm Advisors buys $6,395,367 stake in Pfizer (PFE)

Pfizer (PFE) : Klcm Advisors scooped up 173,704 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 181,945 shares of Pfizer which is valued at $6,395,367.Pfizer makes up approximately 2.09% of Klcm Advisors’s portfolio.

Other Hedge Funds, Including , Kidder Stephen W boosted its stake in PFE in the latest quarter, The investment management firm added 300 additional shares and now holds a total of 11,161 shares of Pfizer which is valued at $392,309. Pfizer makes up approx 0.15% of Kidder Stephen W’s portfolio.Blackhill Capital Inc reduced its stake in PFE by selling 3,000 shares or 0.45% in the most recent quarter. The Hedge Fund company now holds 661,301 shares of PFE which is valued at $23,436,507. Pfizer makes up approx 3.76% of Blackhill Capital Inc’s portfolio.Clark Estates Incny reduced its stake in PFE by selling 50,000 shares or 4.73% in the most recent quarter. The Hedge Fund company now holds 1,007,896 shares of PFE which is valued at $35,568,650. Pfizer makes up approx 6.68% of Clark Estates Incny’s portfolio.Investment Partners Ltd Oh Adv reduced its stake in PFE by selling 31,474 shares or 51.8% in the most recent quarter. The Hedge Fund company now holds 29,282 shares of PFE which is valued at $1,063,229. Pfizer makes up approx 1.04% of Investment Partners Ltd Oh Adv’s portfolio.

Pfizer opened for trading at $35.05 and hit $35.17 on the upside on Monday, eventually ending the session at $35.11, with a gain of 0.37% or 0.13 points. The heightened volatility saw the trading volume jump to 1,23,54,034 shares. Company has a market cap of $212,965 M.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.